Jeffrey Curtis
Rheumatology · Birmingham, ALNPI 1669415725
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $515,341 of the $612,072 with a category attached, or 84.2%. It is spread thinly across 34 manufacturers, the largest accounting for just 12.7%. Reporting peaked in 2019 at $160,964 and has fallen 69.1% since, to $49,770 in 2025. Among rheumatology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $1789.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$77K
- Radius Health, Inc.$64K
- Pfizer$60K
- Janssen Scientific Affairs, LLC$56K
- Sanofi$53K
- Eli Lilly$45K
- plus $256K from 28 others
Across 181 payments — averaging $94,468 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$13.8M
- Pfizer$2.1M
- AbbVie$720K
- Novartis$170K
- Radius Health, Inc.$161K
- E.r. Squibb & Sons, L.L.C.$85K
- plus $64K from 7 others
What the payments were for
- Consulting fees$515,34184%
- Speaking & faculty fees$52,2439%
- Travel & lodging$36,5446%
- Food & beverage$3,9961%
- Education$3,9471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 43 | $77,494 |
| Radius Health, Inc. | 19 | $63,939 |
| Pfizer | 21 | $59,925 |
| Janssen Scientific Affairs, LLC | 26 | $56,299 |
| Sanofi | 22 | $52,934 |
| Eli Lilly | 19 | $45,129 |
| AbbVie | 24 | $37,218 |
| GSK | 22 | $31,037 |
| Modernatx, Inc. | 16 | $24,194 |
| UCB SA | 5 | $18,966 |
| Sandoz | 6 | $16,448 |
| Johnson & Johnson | 16 | $15,923 |
| Regeneron | 21 | $15,118 |
| Novartis | 11 | $14,799 |
| UCB, Inc. | 20 | $14,367 |
| Gilead | 16 | $12,459 |
| E.r. Squibb & Sons, L.L.C. | 4 | $11,950 |
| Sanofi-aventis U.S. LLC | 10 | $11,593 |
| Sanofi US Services Inc. | 3 | $9,744 |
| Astrazeneca UK Limited | 3 | $7,518 |
| Inova Diagnostics, Inc. | 2 | $4,860 |
| Whitehall International Inc | 1 | $3,400 |
| Invivyd Inc | 1 | $2,013 |
| Mylan Inc. | 1 | $1,563 |
| F. Hoffmann-la Roche AG | 1 | $840 |
| Cumberland Pharmaceuticals, Inc. | 1 | $750 |
| Fresenius Kabi USA, LLC | 1 | $650 |
| Samsung Bioepis Co., Ltd. | 1 | $550 |
| Cardinal Health 110 LLC | 1 | $138 |
| Janssen Research & Development, LLC | 1 | $82 |
| Encore Medical, LP | 1 | $71 |
| Regeneron Healthcare Solutions, Inc. | 1 | $49 |
| Biotissue Holdings Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEVZARA$70,914
- XELJANZ$52,300
- REMICADE$45,966
- SIMPONI ARIA$40,384
- EVENITY$33,685
- Tremfya$32,516
- Moderna Covid-19 Vaccine$24,053
- Enbrel$23,825
- Prolia$17,242
- Rinvoq$16,500
- COSENTYX$14,705
- STELARA$12,499
- ORENCIA$8,950
- NO PRODUCT DISCUSSED$7,533
- Tymlos$6,737
- Cimzia$5,785
- Otezla$5,732
- Bimzelx$3,923
- SHINGRIX$3,250
- Rystiggo$3,195
How this compares
$612,072 in reported general payments places this provider in the 95th percentile of 90 rheumatology providers in Alabama.
Other rheumatology in Birmingham
- David McLainBirmingham$588K
- Kenneth SaagBirmingham$143K
- Maria DanilaBirmingham$46K
- Matthew MullenBirmingham$38K
- Angelo Gaffo LlontopBirmingham$36K
- Greg EudyBirmingham$33K
- John MorganBirmingham$11K
- Jose Rubio MosqueraBirmingham$8K
- Kurt BlakeBirmingham$7K
- Amanda AlexanderBirmingham$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.